Skip to main content
. 2006 Dec 7;117(1):218–228. doi: 10.1172/JCI28803

Figure 6. RB/E2F downstream target deregulation correlates with poor prognosis in human breast cancers treated with Tam monotherapy.

Figure 6

(A) Gene expression data from 60 ER-positive human breast tumors that were both micro- and macrodissected were analyzed for RB/E2F target gene expression using GeneSpring. The expression patterns of 59 known RB/E2F target genes and the expression levels of Rb, p16, cyclin D1, and cyclin E are displayed in a condition tree for each of the 2 tissue samples from each patient (120 samples). The average RB/E2F target gene expression levels of all 59 genes were categorized into 3 groups: low, medium, and high. Three HER2/neu-positive tumors (a, b, and c) were present in this tumor set. (B) The RB/E2F target gene expression levels in each group represented in C were averaged and displayed as a box-and-whisker plot. A 2-tailed Student’s t test assuming unequal variances was utilized to determine significance (P = 7.2 × 10–12 low/medium; P = 1.3 × 10–14 medium/high). (C) The survival data for each of the 60 patients from the low/medium and high gene expression groups represented in C was compiled into a disease-free survival curve. Statistical tests were performed as described for B.